Patent intelligence · US
US 8791074
Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors
Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases …
Patent details — US 8791074
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 29, 2014
- Expiration
- Jul 24, 2034
- Claims
- 17
- CPC classes
- A61K, A61K38/00, A61K47/665, A61P
Quick answer
US 8791074 (Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors) is held by The United States of America, as represented by the Secretary, Department of Health and Human Services. Status: granted. Granted Jul 29, 2014. Expires Jul 24, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K38/00, A61K47/665, A61P, A61P35/00
More from The United States of America, as represented by the Secretary, Department of Health and Human Services
Related pharmaceutical patents in our USPTO index.
-
US 12419873
Use of JAK inhibitors in preparation of drugs for treating JAK kinase-related diseases
granted -
US 12419941
Poultry drinking water-based vaccine delivery system and method
granted -
US 12415845
Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof
granted -
US 12410240
Antibodies and methods for the diagnosis and treatment of Epstein Barr virus infection
granted -
US 12410259
CD47 targeted therapies for the treatment of infectious disease
granted -
US 12404317
T cell receptors recognizing MHC class II-restricted MAGE-A3
granted -
US 12397066
Delivery of gene therapy treatments
granted -
US 12398123
Chemical inhibition of the E3 ligase subunit FBXO7 confers neuroprotection and anti-inflammatory activity by stabilizing mitochondria
granted
Frequently asked questions
What is US patent 8791074?
US 8791074 (Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors) is held by The United States of America, as represented by the Secretary, Department of Health and Human Services. Status: granted. Granted Jul 29, 2014. Expires Jul 24, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8791074?
The United States of America, as represented by the Secretary, Department of Health and Human Services is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3,720 pharmaceutical patents for this assignee.
When does US 8791074 expire?
Our index shows an expiration date of Jul 24, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.